4 results about "EGFR L858R" patented technology

The invention belongs to the technical field of gene mutation detection, and particularly relates to an isothermal amplification method and a kit for detecting EGFR-L858R and EGFR-T790M point mutation. One purpose of the invention is to provide a kit for detecting EGFR-L858R and EGFR-T790M point mutation. The kit comprises a capture probe sequence as shown in SEQ ID NO.5 and a signal probe sequence as shown in SEQ ID NO.6, wherein the capture probe sequence is used for detecting L858R point mutation; a capture probe sequence as shown in SEQ ID NO.10 and a signal probe sequence as shown in SEQ ID NO.11, which are used for detecting T790M point mutation. According to the technical scheme, PdAgBP is taken as a solid-phase immobilized substrate, EXPAR isothermal amplification and nucleic acid site LNA padlock are taken as a dual signal amplification mechanism, and biosensors based on BPE-ECL are respectively constructed for detection of point mutation EGFR L858R and EGFR T790M.

The present invention provides a novel therapeutic means for cancer cells resistant to epidermal growth factor receptor (EGFR)-targeted anticancer agents. Almost no cell death was observed when cancer cells having an exon 19 deletion mutation in the EGFR gene (EGFR Del19), cancer cells having a substitution mutation in which the 790th amino acid threonine in the EGFR protein is substituted with methionine (EGFR T790M), and cancer cells having a substitution mutation in which the 858th amino acid leucine is substituted with arginine (EGFR L858R) were treated solely with aripiprazole or solely with an EGFR-targeted anticancer agent. However, cell viability decreased and cleavage of the apoptosis marker PARP was observed when the cancer cells were treated with aripiprazole in combination with an EGFR-targeted anticancer agent. Therefore, aripiprazole is provided as an enhancer of the anticancer effect of EGFR-targeted anticancer agents.

The application belongs to the technical field of antitumor drugs, and particularly relates to a 2,4-disubstituted quinazoline compound for inhibiting EGFR, a preparation method and application. As a 2,4-disubstituted quinazoline compound for targeting EGFR L858R / T790M, the compound comprises a compound shown in the following formula or a pharmaceutically acceptable salt thereof. The compound or the pharmaceutically acceptable salt thereof has the activity of inhibiting EGFR L858R / T790M, can be used as an inhibitor of EGFR L858R / T790M, has the activity of resisting tumors, and can effectively inhibit the growth of tumor cells.

This invention relates to the field of biodetection technology, providing a logic-gated nanogel probe for live cell typing and its preparation method. The invention uses a thermosensitive polymer nanogel as a carrier, with its surface covalently modified with an antibody that specifically binds to the EGFR L858R mutant protein and a peptide nucleic acid that specifically binds to miR-21. Internally, it encapsulates a self-quenched fluorescent dye. The probe employs an AND logic gating design, triggering gel network dissociation and dye release to generate a fluorescent signal only when it simultaneously recognizes the EGFR L858R protein on the cell surface and captures miR-21 within the cell. This invention solves the problems of high false positive rates in existing single-target detection methods and the inability of traditional liquid biopsy techniques to perform simultaneous genotype-phenotype analysis in situ on live cells. It achieves highly specific and sensitive in situ interpretation of circulating tumor cells, and has significant application value in the field of precision diagnosis and treatment of lung cancer.